

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TenNor Therapeutics (Suzhou) Limited

丹諾醫藥(蘇州)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6872)

VOLUNTARY ANNOUNCEMENT
COMPLETION OF ENROLLMENT OF THE FIRST PATIENT IN THE
MULTI-CENTER PHASE IIB CLINICAL TRIAL OF RIFAQUIZINONE
(TNP-2092) ADMINISTERED VIA INTRA-ARTICULAR INJECTION
FOR THE TREATMENT OF PROSTHETIC JOINT INFECTION

This announcement is made by TenNor Therapeutics (Suzhou) Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders and potential investors of the Company informed of the latest business developments of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that the multi-center Phase Iib clinical trial of the Company’s new drug candidate, rifaquizinone (TNP-2092), administered via intra-articular injection for the treatment of prosthetic joint infection (“**PJI**”) has completed the enrollment of the first patient. This trial is designed to further evaluate the efficacy, safety and pharmacokinetic profile of rifaquizinone (TNP-2092) in the treatment of PJI without debridement or revision surgery, marking that this potentially disruptive therapy has entered a key stage of clinical development.

The Phase Iib clinical trial is a randomized, controlled, open-label multi-center clinical study (trial identifier: NCT07858916; China drug clinical trial registration number: CTR20263531), with a planned enrollment of 40 adult subjects. The trial will evaluate the efficacy, safety and pharmacokinetic profile of rifaquizinone administered via intra-articular injection, together with background systemic antimicrobial therapy while avoiding debridement or replacement surgery, in patients with early postoperative (within 3 months after surgery) or acute hematogenous (within 4 weeks of infection symptoms) PJI following knee arthroplasty. It will also evaluate the efficacy of rifaquizinone administered via intra-articular injection in patients with chronic PJI requiring long-term antibiotic suppression therapy. The primary study endpoint is the efficacy at 6 months after the initiation of the study treatment.

About PJI

PJI is a serious complication following joint replacement surgery that can transform an initially successful operation into a crisis for both the healthcare and patients. In the United States, there are approximately 45,000 new cases of PJI each year, while there are approximately 22,000 cases in China, with the incidence showing a rapid upward trend. However, the treatment of PJI faces significant challenges as the formation of bacterial biofilms substantially reduces the efficacy of conventional antimicrobial agents. Treatment regimens that rely solely on antimicrobial agents without surgical intervention are not recommended in clinical practice due to their extremely high failure rates.

Currently, all available treatment options for patients require surgical intervention, yet treatment outcomes remain suboptimal: for early postoperative or acute hematogenous PJI, guidelines recommend debridement, antibiotics, and implant retention (DAIR) procedures, but reported failure rates exceed 30%. For chronic PJI, a two-stage revision arthroplasty is required, which involves multiple surgeries, prolonged hospitalization and several months of functional loss postoperatively, with failure rates still exceeding 10%. The economic burden of PJI is extremely heavy, with treatment costs in the United States typically exceeding US\$390,000 per patient. Meanwhile, the continued growth in joint replacement surgeries further intensifies the clinical challenge, driving a rapid increase in PJI incidence. It is estimated that by 2035, the number of new PJI cases globally will reach 425,800 per year, of which China is projected to account for 86,500 cases.

About Rifaquizinone (TNP-2092)

Rifaquizinone is the world's first new drug candidate developed specifically to target the significant unmet clinical need for biofilm infections associated with implantable medical devices through a triple-targeting mechanism of action. Through its unique triple-targeting synergistic mechanism of action by simultaneously inhibiting bacterial RNA polymerase, DNA gyrase and DNA topoisomerase IV, rifaquizinone not only demonstrates potent bactericidal activity against drug-resistant pathogens (including methicillin-resistant *S. aureus* and quinolone-resistant *S. aureus*), but also reduces the resistance frequency to an extremely low level ($<10^{-12}$).

In the preclinical study, rifaquizinone has demonstrated strong *in vitro* and *in vivo* biofilm bactericidal activity, and its efficacy is significantly superior to that of current standard-of-care antibiotics. The Company has successfully completed six Phase I and Phase II clinical trials in the U.S. and China, and the intravenous administration of rifaquizinone has demonstrated favorable safety and excellent efficacy profile in the treatment of acute bacterial skin and skin structure infections.

The transformative potential of rifaquizinone has been highly recognized by regulatory authorities. Rifaquizinone has been granted Qualified Infectious Disease Product, Fast Track, and Orphan Drug designations by the United States Food and Drug Administration. In addition, rifaquizinone has also received the outstanding award at the National Disruptive Technology Innovation Competition in China (中國全國顛覆性技術創新大賽優勝獎).

About the Company

The Company is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet clinical needs in disease areas associated with bacterial infections and bacterial metabolism. Relying on its proprietary multi-targeting conjugate molecule technology platform, the Company aims to deliver therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes.

As of the date of this announcement, the Company had established a drug research and development pipeline comprising eight innovative programs, including two core products, namely: rifasutenizol (TNP-2198), a multi-targeting conjugated new molecular entity (“NME”) candidate for the treatment of *Helicobacter pylori* infection when used in combination with amoxicillin and a proton pump inhibitor, as well as monotherapy for bacterial vaginosis and *Clostridioides difficile* infection; and rifaquizinone (TNP-2092) injection, a triple-targeting NME candidate for the treatment of acute bacterial skin and skin structure infection and implant-associated bacterial infections (such as PJI, left ventricular assist device infection and catheter-related bloodstream infection).

Forward-looking Statements

Specific information in this announcement may contain or constitute forward-looking statements that are not historical facts. Forward-looking statements can be identified by using forward-looking terminology, such as “predict”, “believe”, “plan”, “estimate”, “expect”, “will”, “may”, “should” and other words of similar meanings. Based on the current beliefs, plans, estimates and expectations of the management of the Company in respect of the Group’s operation and market trends subject to changes beyond control, the forward-looking statements reflect the Company’s beliefs, plans, estimates and expectations of future development. Actual outcome may differ significantly from forward-looking statements owing to market, policy, and research and development uncertainties, among others. Subject to the above-mentioned uncertainties, the Company makes no expressed or implied guarantee as to the accuracy, completeness or feasibility of such statements, and you are cautioned not to solely rely on such forward-looking statements. Neither the Company nor any of its directors, officers, employees, shareholders, agents, related parties, consultants or representatives will be liable to you or any other person for consequences resulting from using such statements. You are advised to exercise due diligence with reference to the Company’s official disclosure documents for decision-making.

We may not be able to ultimately develop and market rifaquizinone (TNP-2092) successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
TenNor Therapeutics (Suzhou) Limited
Dr. Ma Zhenkun
*Chairman of the Board, Executive Director,
Chief Executive Officer and General Manager*

Hong Kong, 23 October 2026

As at the date of this announcement, the Board comprises: (i) Dr. Ma Zhenkun as an executive Director; (ii) Dr. Song Gaoguang as a non-executive Director; and (iii) Mr. Lee Wai Kong, Albert, Dr. Ni Lin and Dr. Li Leping as independent non-executive Directors.